CRYBG2

Across TCGA pan-cancer cohorts, CRYBG2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CRYBG2 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CRYBG2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CRYBG2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where CRYBG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	1.000	0.344	.009	37	view →
LSCC	DFS	Median	All	0.999	0.865	.003	26	view →
PDAC	DFS	Quartile	All	0.510	0.301	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CRYBG2–HNSC (OS)

Open the HNSC breakdown →